selpercatinib
E561036
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
All labels observed (1)
| Label | Occurrences |
|---|---|
| selpercatinib canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003722 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: selpercatinib Context triple: [Loxo Oncology, developedDrug, selpercatinib]
-
A.
Tagrisso
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: selpercatinib Target entity description: Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
A.
Tagrisso
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
RET inhibitor
ⓘ
small molecule drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToChemicalClass | small-molecule kinase inhibitors ⓘ |
| developedBy | Eli Lilly and Company NERFINISHED ⓘ |
| firstApprovalYear | 2020 ⓘ |
| firstApprovedIn | United States NERFINISHED ⓘ |
| hasAdministrationFrequency | twice daily in many regimens ⓘ |
| hasApprovalType | accelerated approval (initial US approval) ⓘ |
| hasATCCode | L01EX19 ⓘ |
| hasBlackBoxWarning | none (as of initial approval) ⓘ |
| hasBrandName | Retevmo NERFINISHED ⓘ |
| hasCommonAdverseEffect |
constipation
ⓘ
diarrhea ⓘ dry mouth ⓘ edema ⓘ elevated liver enzymes ⓘ fatigue ⓘ hypertension ⓘ |
| hasDosageForm | capsule ⓘ |
| hasDrugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| hasIndicationPopulation |
adult patients
ⓘ
pediatric patients 12 years and older ⓘ |
| hasINN | selpercatinib ⓘ |
| hasMechanismOfAction |
inhibition of RET-mediated signaling pathways
ⓘ
selective RET kinase inhibition ⓘ |
| hasMolecularTargetType | receptor tyrosine kinase ⓘ |
| hasPregnancyRisk | may cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for RET over many other kinases ⓘ |
| hasSeriousAdverseEffect |
QT interval prolongation
ⓘ
hemorrhagic events ⓘ hepatotoxicity ⓘ interstitial lung disease ⓘ |
| hasTarget |
RET kinase
NERFINISHED
ⓘ
rearranged during transfection proto-oncogene ⓘ |
| indicatedFor |
RET fusion-positive non-small cell lung cancer
ⓘ
RET-mutant medullary thyroid carcinoma ⓘ advanced RET fusion-positive thyroid cancer ⓘ metastatic RET fusion-positive non-small cell lung cancer ⓘ metastatic RET-mutant medullary thyroid cancer ⓘ |
| isAdministered | by mouth ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| isTakenWithFood | may be taken with or without food ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: selpercatinib Description of subject: Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology
subject surface form:
Loxo Oncology